AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01234272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
Study NCT02004080 — intervention group
Intervention type: OTHER
Intervention: Intensive Care treatment
Description: intensive care treatment
Study NCT00716755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone/Olanzapine and PET scans
Description: Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
Study NCT01380431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Tablets, 40 mg, single oral dose
Study NCT01380431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: Tablets, 40 mg, single, oral dose
Study NCT01380431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: 50% of subjects received the Par formulated product.
Study NCT03042208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self guided handout
Description: Written handout with basic weight management strategies
Study NCT03042208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: Access to Weight Watchers in-person meetings and online tools
Study NCT02030743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visual training
Description: 6 training sessions with computerised visual attention paradigm
Study NCT02030743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual training
Description: 6 training sessions with computerised visual attention paradigm
Study NCT01332539 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study
Study NCT01295216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile technology to promote lifestyle modification
Description: Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
Study NCT02613390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI images of the spine taken of anesthetized participant in the operative prone position.
Study NCT02613390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Pain and symptom questionnaires completed at baseline and at follow up.
Study NCT04197115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT04197115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT04197115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Complex B
Description: Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
Study NCT01258907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single intravenous dose
Study NCT01258907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Repeating intravenous dose
Study NCT01258907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating intravenous dose
Study NCT01258907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin, stable dose
Description: Repeating oral dose
Study NCT01258907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: statin, stable dose
Description: Repeating oral dose
Study NCT01430039 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
Study NCT01430039 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample - venous blood 10 ml.
Description: venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
Study NCT03922698 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study NCT01358955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based cognitive intervention
Description: The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
Study NCT01252225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 % Lidocaine
Description: 600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
Study NCT01252225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 % Lidocaine
Description: 100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
Study NCT01252225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
Study NCT03976648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: film-coated tablets of GLPG1690 to be administered orally
Study NCT03265652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy
Description: Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
Study NCT03265652 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham therapy
Description: Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
Study NCT03961438 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
Description: Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
Study NCT03961438 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
Description: Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
Study NCT00003496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02042872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
Study NCT01006291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
Study NCT01006291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study NCT01006291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study NCT02105662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Description: MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
Study NCT03063034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AA
Description: A king size menthol cigarette.
Study NCT03063034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD21864AB
Description: A king size menthol cigarette.
Study NCT04463459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin E
Description: Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
Study NCT03079102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
Study NCT03079102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
Study NCT03574519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-contingent incentives
Description: Incentives are provided for participation
Study NCT03574519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent incentives
Description: Incentives are provided for attaining daily goals
Study NCT03574519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly feedback
Description: Text message feedback is delivered weekly summarizing the past week's progress
Study NCT03574519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Text message feedback is delivered daily summarizing the current day's progress
Study NCT02479308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single administration
Study NCT02479308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Daily administration for a total of 12 dosing days
Study NCT02479308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched to Moxifloxacin or ALKS 5461
Study NCT04606329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LuminoMark inj.(Conc. for fluorescence)
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Study NCT04606329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcotrace Inj.
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Study NCT04177576 — intervention group
Intervention type: BIOLOGICAL
Intervention: 2 additional tubes of blood
Description: 2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
Study NCT02800629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Citrus Pectin
Description: MCP versus placebo
Study NCT02800629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01074593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 12.000UI - single dose
Study NCT01074593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: 12.000UI - Single dose
Study NCT03788772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple blood sampling
Description: ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
Study NCT03788772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple blood sampling
Description: Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
Study NCT00295880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The graft will be given by slow injection into each posterior iliac crest.
Study NCT03773796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nabilone 0.25 mg
Description: capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
Study NCT03192371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
Study NCT02175199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses with color printing
Study NCT02175199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lenses with color printing
Study NCT01111578 — intervention group
Intervention type: DEVICE
Intervention: Enteral feeding tube
Description: The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
Study NCT02260180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study NCT02260180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study NCT04319692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Prunus Mume Vinegar group
Description: This group takes Fermented Prunus Mume Vinegar for 8 weeks
Study NCT04319692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes placebo for 8 weeks.
Study NCT02664948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early geriatric follow-up after discharge
Description: Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
Study NCT01043289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
Study NCT01043289 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Light therapy
Description: During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
Study NCT01048632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: 2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
Study NCT01047605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas balance
Description: 6 tablets single dose
Study NCT01047605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pascoflair 425 mg
Description: 3 tablets , single dose
Study NCT01047605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-Tabletten weiß
Description: 3 tablets, single dose
Study NCT01322841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Diagnosis Module
Description: The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
Study NCT01322841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHICA Placebo
Description: This was CHICA without the screening module
Study NCT04065737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308
Study NCT02513927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
Study NCT02513927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
Study NCT02273596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Individualized oral doses of ALXN1840.
Study NCT02267876 — intervention group
Intervention type: DEVICE
Intervention: BD HPV Assay on Viper LT
Description: The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
Study NCT02267876 — intervention group
Intervention type: PROCEDURE
Intervention: Colposcopy
Description: The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
Study NCT01401660 — intervention group
Intervention type: OTHER
Intervention: Physical Therapy
Description: The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
Study NCT01732601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient CBT
Description: Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
Study NCT01732601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment at step-down facilities
Study NCT01864382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Core stability 5 days a week during 5 weeks
Study NCT01864382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Exercises
Description: Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
Study NCT01864382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Physiotherapy Exercises
Description: Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
Study NCT03565952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial massage
Description: Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
Study NCT03565952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group does not receive treatment
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT04267913 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT04267913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sapanisertib
Description: Given PO